Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP (REACT-2020)

University of Cologne

Status: Enrolling

Conditions: Acquired Thrombotic Thrombocytopenic Purpura

Treatments: Drug: Cablivi®

Study type: Observational

Funder types: Other

Identifiers

NCT04985318

V01-19052020

Details and patient eligibility

About

The objective of this national, prospective, multi-centre observational study is to describe the prescription rational and practice in Germany, confirm the efficacy of caplacizumab in a real-world setting, and identify predicting factors in iTTP-patients with regard to persistent autoimmune activity, therapy guidance and risk of complications. The rational is to develop new treatment algorithms that optimize overall patient outcome and reduce treatment cost.

Enrollment: 350 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Confirmed diagnosis of an acute episode of acquired thrombotic thrombocytopenic purpura
• Treatment with at least one single dose of caplacizumab (10 mg i.v. or s.c.)
• Male or female patients ≥ 18 years of age
• signed written informed consent

Exclusion criteria

• Hereditary thrombotic thrombocytopenic purpura
• disability to give informed consent

Trial design

350 participants in 1 patient group

Registergroup

Description:

Patients with acquired Thrombotic Thrombocytopenic Purpura, who have been treated with caplacizumab (Cablivi®)

Treatment:

Drug: Cablivi®